Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.
His research activities include atherosclerosis, lipid apheresis, vascular inflamation and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.